These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 30236749)

  • 1. Clinical, Patient-Reported, and Ultrasound Outcomes from an Open-Label, 12-week Observational Study of Certolizumab Pegol in Spanish Patients with Rheumatoid Arthritis with or without Prior Anti-TNF Exposure.
    Blanco FJ; Rubio-Romero E; Sanmartí R; Díaz-Torné C; Talavera P; Dunkel J; Naredo E;
    Reumatol Clin (Engl Ed); 2020; 16(5 Pt 1):345-352. PubMed ID: 30236749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical, Ultrasound, and Predictability Outcomes Following Certolizumab Pegol Treatment (with Methotrexate) in Patients with Moderate-to-Severe Rheumatoid Arthritis: 52-Week Results from the CZP-SPEED Study.
    Sarzi-Puttini P; Filippucci E; Adami S; Meroni PL; Batticciotto A; Idolazzi L; De Lucia O; Talavera P; Kumke T; Grassi W
    Adv Ther; 2018 Aug; 35(8):1153-1168. PubMed ID: 30043210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population.
    Weinblatt ME; Fleischmann R; van Vollenhoven RF; Emery P; Huizinga TW; Cutolo M; van der Heijde D; Duncan B; Davies O; Luijtens K; Dougados M
    Arthritis Res Ther; 2015 Nov; 17():325. PubMed ID: 26568428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression.
    Atsumi T; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Yasuda S; Yamanishi Y; Kita Y; Matsubara T; Iwamoto M; Shoji T; Okada T; van der Heijde D; Miyasaka N; Koike T
    Ann Rheum Dis; 2016 Jan; 75(1):75-83. PubMed ID: 26139005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of Rheumatoid Arthritis with Certolizumab Pegol: Results from PROACTIVE, a Non-Interventional Study in the UK and Ireland.
    Kumar N; Naz S; Quinn M; Ryan J; Kumke T; Sheeran T
    Adv Ther; 2018 Sep; 35(9):1426-1437. PubMed ID: 30076523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and safety of anti-tumour necrosis factor therapy with certolizumab pegol observed in real-life rheumatoid arthritis patients in Germany: results from the non-interventional FαsT study.
    Burmester G; Nüsslein H; von Hinüber U; Detert J; Richter C; Kumke T; Leunikava I; Lendl U; Fricke D; Müller-Ladner U
    Clin Exp Rheumatol; 2019; 37(5):842-851. PubMed ID: 30873942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients.
    Smolen JS; van Vollenhoven R; Kavanaugh A; Strand V; Vencovsky J; Schiff M; Landewé R; Haraoui B; Arendt C; Mountian I; Carter D; van der Heijde D
    Arthritis Res Ther; 2015 Sep; 17(1):245. PubMed ID: 26353833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cigarette smoking and clinical response to certolizumab pegol treatment in Hungarian, Czech, and Slovak patients with rheumatoid arthritis: 104-week data from the CIMDORA prospective, non-interventional study.
    Szekanecz Z; Koncz Á; Dunkel J; Vencovský J;
    Clin Exp Rheumatol; 2019; 37(6):1010-1018. PubMed ID: 30963993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study.
    Emery P; Bingham CO; Burmester GR; Bykerk VP; Furst DE; Mariette X; van der Heijde D; van Vollenhoven R; Arendt C; Mountian I; Purcaru O; Tatla D; VanLunen B; Weinblatt ME
    Ann Rheum Dis; 2017 Jan; 76(1):96-104. PubMed ID: 27165179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study.
    Glatt S; Taylor PC; McInnes IB; Schett G; Landewé R; Baeten D; Ionescu L; Strimenopoulou F; Watling MIL; Shaw S
    Ann Rheum Dis; 2019 Aug; 78(8):1033-1040. PubMed ID: 31177099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial.
    Strand V; Mease P; Burmester GR; Nikaï E; Coteur G; van Vollenhoven R; Combe B; Keystone EC; Kavanaugh A
    Arthritis Res Ther; 2009; 11(6):R170. PubMed ID: 19909548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid onset of efficacy predicts response to therapy with certolizumab plus methotrexate in patients with active rheumatoid arthritis.
    Kang YM; Park YE; Park W; Choe JY; Cho CS; Shim SC; Bae SC; Suh CH; Cha HS; Koh EM; Song YW; Yoo B; Lee SS; Park MC; Lee SH; Arendt C; Koetse W; Lee SK
    Korean J Intern Med; 2018 Nov; 33(6):1224-1233. PubMed ID: 29294598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.
    Ruiz Garcia V; Burls A; Cabello JB; Vela Casasempere P; Bort-Marti S; Bernal JA
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD007649. PubMed ID: 28884785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial.
    Smolen JS; Emery P; Ferraccioli GF; Samborski W; Berenbaum F; Davies OR; Koetse W; Purcaru O; Bennett B; Burkhardt H
    Ann Rheum Dis; 2015 May; 74(5):843-50. PubMed ID: 24431394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study.
    Weinblatt ME; Fleischmann R; Huizinga TW; Emery P; Pope J; Massarotti EM; van Vollenhoven RF; Wollenhaupt J; Bingham CO; Duncan B; Goel N; Davies OR; Dougados M
    Rheumatology (Oxford); 2012 Dec; 51(12):2204-14. PubMed ID: 22923753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension.
    Keystone E; Landewé R; van Vollenhoven R; Combe B; Strand V; Mease P; Shaughnessy L; VanLunen B; van der Heijde D
    Ann Rheum Dis; 2014 Dec; 73(12):2094-100. PubMed ID: 23918037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvements in productivity and increased participation in daily activities over 52 weeks of certolizumab pegol treatment of rheumatoid arthritis: results of a Belgian observational study.
    Westhovens R; Ravelingien I; Vandevyvere K; Pansar I; Purcaru O; Kumke T; Gyselbrecht L
    Acta Clin Belg; 2019 Oct; 74(5):342-350. PubMed ID: 30160189
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial.
    Walsh JA; Gottlieb AB; Hoepken B; Nurminen T; Mease PJ
    Clin Rheumatol; 2018 Dec; 37(12):3285-3296. PubMed ID: 30191421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Matrix metalloproteinase-3 and the 7-joint ultrasound score in the assessment of disease activity and therapeutic efficacy in patients with moderate to severe rheumatoid arthritis.
    Zhou L; Wang G; Liu X; Song J; Chen L; Xu H
    Arthritis Res Ther; 2017 Nov; 19(1):250. PubMed ID: 29141665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early non-response to certolizumab pegol in rheumatoid arthritis predicts failure to achieve low disease activity at 1 year: data from a prospective observational study.
    Saraux A; Flipo RM; Fagnani F; Massol J; Cukierman G; Joubert JM; Huot-Marchand P; Combe B
    RMD Open; 2020 Jan; 6(1):. PubMed ID: 31958276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.